Prolonged and Severe SARS-CoV-2 Infection in Patients Under B-cell-depleting Drug Successfully Treated: A Tailored Approach

Overview

Journal Int J Infect Dis

Publisher Elsevier

Specialty Infectious Diseases

Date 2021 Apr 26

PMID 33901654

Citations 27

Authors

Alessandra DAbramo

Serena Vita

Gaetano Maffongelli

Andrea Mariano

Chiara Agrati

Concetta Castilletti

Delia Goletti

Giuseppe Ippolito

Emanuele Nicastri

Affiliations

Soon will be listed here.

Abstract

Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response, causing severe manifestations during COronaVIrus Disease-2019 (COVID-19). The cases of two patients under anti-CD20 therapy who experienced prolonged and severe COVID-19 successfully treated with mAbs against Severe Acute Respiratory Syndrome-CoV-2 spike proteins are reported.

Citing Articles

The consequences of SARS-CoV-2 within-host persistence.

Sigal A, Neher R, Lessells R Nat Rev Microbiol. 2024; .

PMID: 39587352 DOI: 10.1038/s41579-024-01125-y.

Immune Cells Are Differentially Affected by SARS-CoV-2 Viral Loads in K18-hACE2 Mice.

Kim J, Kim S, Kim J, Noh H, Lee S, Jeong H Immune Netw. 2024; 24(2):e7.

PMID: 38725670 PMC: 11076298. DOI: 10.4110/in.2024.24.e7.

B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience.

DAbramo A, Vita S, Beccacece A, Navarra A, Pisapia R, Fusco F Front Med (Lausanne). 2024; 11:1344267.

PMID: 38487021 PMC: 10937561. DOI: 10.3389/fmed.2024.1344267.

Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.

Aiello T, Peyrony O, Chumbita M, Monzo P, Lopera C, Puerta-Alcalde P Influenza Other Respir Viruses. 2024; 18(3):e13264.

PMID: 38468434 PMC: 10928260. DOI: 10.1111/irv.13264.

Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report.

Vita S, DAbramo A, Coppola A, Farroni C, Iori A, Faraglia F Front Oncol. 2024; 14:1290614.

PMID: 38414746 PMC: 10896944. DOI: 10.3389/fonc.2024.1290614.

References

Rydyznski Moderbacher C, Ramirez S, Dan J, Grifoni A, Hastie K, Weiskopf D . Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020; 183(4):996-1012.e19. PMC: 7494270. DOI: 10.1016/j.cell.2020.09.038. View

Hueso T, Pouderoux C, Pere H, Beaumont A, Raillon L, Ader F . Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020; 136(20):2290-2295. PMC: 7702482. DOI: 10.1182/blood.2020008423. View

Iannetta M, Cesta N, Stingone C, Malagnino V, Teti E, Vitale P . Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. Mult Scler Relat Disord. 2020; 45:102442. PMC: 7399651. DOI: 10.1016/j.msard.2020.102442. View

Weinreich D, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R . REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2020; 384(3):238-251. PMC: 7781102. DOI: 10.1056/NEJMoa2035002. View

Jiang Y, Chen D, Cai D, Yi Y, Jiang S . Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis. J Med Virol. 2020; 93(2):1171-1174. PMC: 7461548. DOI: 10.1002/jmv.26443. View

Hawker K, OConnor P, Freedman M, Calabresi P, Antel J, Simon J . Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009; 66(4):460-71. DOI: 10.1002/ana.21867. View

Chisari C, Sgarlata E, Arena S, Toscano S, Luca M, Patti F . Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2021; 269(1):159-183. PMC: 7790722. DOI: 10.1007/s00415-020-10362-z. View

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

Crawford A, MacLeod M, Schumacher T, Corlett L, Gray D . Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol. 2006; 176(6):3498-506. DOI: 10.4049/jimmunol.176.6.3498. View

10.

Colavita F, Lapa D, Carletti F, Lalle E, Messina F, Rueca M . Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics. Open Forum Infect Dis. 2021; 7(10):ofaa403. PMC: 7499768. DOI: 10.1093/ofid/ofaa403. View

11.

Cantini F, Niccoli L, Capone A, Petrone L, Goletti D . Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019; 18(5):415-425. DOI: 10.1080/14740338.2019.1612872. View

12.

Mehta P, Porter J, Chambers R, Isenberg D, Reddy V . B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?. Lancet Rheumatol. 2021; 2(10):e589-e590. PMC: 7836835. DOI: 10.1016/S2665-9913(20)30270-8. View

13.

Sormani M, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L . Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021; 89(4):780-789. PMC: 8013440. DOI: 10.1002/ana.26028. View

14.

He W, Chen L, Chen L, Yuan G, Fang Y, Chen W . COVID-19 in persons with haematological cancers. Leukemia. 2020; 34(6):1637-1645. PMC: 7180672. DOI: 10.1038/s41375-020-0836-7. View

15.

Hughes R, Whitley L, Fitovski K, Schneble H, Muros E, Sauter A . COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord. 2021; 49:102725. PMC: 7772086. DOI: 10.1016/j.msard.2020.102725. View